Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1406 - Simultaneous Resection of Pancreatic Cancer and Liver Oligometastases After Induction Chemotherapy in Stage IV Patients:an Open-Label Prospective Randomized Multicenter phase 3 trial(CSPAC-1)

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Miaoyan Wei

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

M. Wei1, S. Shi1, J. Xu1, B. Shen2, Y. Mou3, R. Qin4, W. Fang5, R. Chen6, W. Wang7, C. Shao8, X. Yu1

Author affiliations

  • 1 Department Of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Research Institute Of Pancreatic Diseases, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, 200020 - Shanghai/CN
  • 3 Department Of General Surgery, Zhejiang Provincial People’s Hospita, 310015 - Hangzhou/CN
  • 4 Department Of Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,, 430030 - Wuhan/CN
  • 5 Department Of Medical Oncology, The First Hospital of Zhejiang Province, 310003 - Hangzhou/CN
  • 6 Department Of Pancreatic Surgery, Sun Yat-Sen Memorial Hospital҅ Sun Yat-Sen University,, 510120 - Guangzhou/CN
  • 7 Department Of Pancreatic Surgery, Huadong Hospital Affiliated to Fudan University, 200040 - Shanghai/CN
  • 8 Department Of Pancreatic Surgery, Shanghai Changzheng Hospital, 200003 - Shanghai/CN
More

Resources

Abstract 1406

Background

Approximately 40% pancreatic ductal adenocarcinoma (PDAC) patients (pts) are diagnosed with distant metastasis, especially liver metastasis. The current standard treatment for these Stage IV pts is palliative chemotherapy. However, the improved safety of pancreatic surgery has led to the consideration of more aggressive approaches. There is increasing agreement that the synchronous resection of PDAC and liver metastases may benefit highly selected pts. Thus, CSPAC-1 trial to evaluate a treatment strategy for selecting pts who can benefit from the synchronous resection after induction chemotherapy is launched by Chinese Study Group for Pancreatic Cancer (CSPAC).

Trial design

Liver oligometastases is defined as no more than 3 metastatic lesions irrespective of distribution within liver lobes. The study contains two steps. In the first step, 1000∼1200 cases of stage IV PDAC pts 18∼75 yo who had pathologically confirmed via needle biopsy from hepatic oligometastases or pancreatic lesions, ECOG 0∼1 are eligible for inclusion. Candidates will receive standard first-line chemotherapy including standard or modified FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin), NG (nab-paclitaxel plus gemcitabine) or GS (gemcitabine plus S-1). RECIST v1.1 criteria combining with tumor markers would be applied to evaluate tumor response to chemotherapy every two cycles. Approximately 30% surgical conversion rate after induction chemotherapy can be achieved according to our prior small sample study. 300 pts who meet the criteria for intervention will get access to the second step and be randomly assigned in a 1:1 ratio to simultaneous resection of primary PDAC and liver oligometastases or standard chemotherapy. The primary outcome of this clinical trial is real overall survival (from enrollment to death). Main secondary outcome measures including overall survival (from randomization to death), life quality score, postoperative morbidity, and mortality. This study was activated in July 2018 and is expected to complete accrual within 5 years.

Clinical trial identification

NCT03398291.

Editorial acknowledgement

Legal entity responsible for the study

The Chinese Study Group for Pancreatic Cancer (CSPAC), Shanghai Shenkang Hospital Development Center, BeiGene Pharmaceutical Co., Ltd.

Funding

The Chinese Study Group for Pancreatic Cancer (CSPAC), Shanghai Shenkang Hospital Development Center, BeiGene Pharmaceutical Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.